Regulations are stifling development of new drugs

BMJ 2004; 328 doi: (Published 11 March 2004) Cite this as: BMJ 2004;328:600
  1. Zosia Kmietowicz
  1. London

    The volumes of regulations that surround scientific research are stifling the development of new drugs and need to be rationalised if innovative discoveries in biology are to be matched with new medicines and demand by patients for better treatments, said experts this week.

    It costs an estimated $800m (£433m; €645m) to get a new drug to the market, and pharmaceutical companies have to hit …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to to receive unlimited access to all content on for 14 days.
    Sign up for a free trial